Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to antibiotics and innovation and the safety of prescription drugs, over-the-counter medicines, and other consumer health care products.
Before joining Pew, she served as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.
Before moving to the Hill, Jungman was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She serves on FDA’s Pharmacy Compounding Advisory Committee and represents Pew as a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. She has an undergraduate biology degree from Harvard College, a Juris Doctor from Georgetown University, and a master’s degree in public health from Johns Hopkins University.
Recent WorkView All
The Pew Charitable Trusts, together with the American Public Health Association, the Association for Accessible Medicines, the Biotechnology Innovation Organization, the Pharmaceutical Research and Manufacturers of America, and Trust for America’s Health sent letters to the chairs and ranking members of the Appropriations Committees of the U.S. Senate and the U.S. House of... Read More
Policymakers have implemented important reforms since the meningitis outbreak; however, federal and state officials have further to go to protect patients from the dangers posed by the compounders engaged in risky, or even illegal, behavior. Read More
The Pew Charitable Trusts offered comments on a revised draft guidance document issued by the Food and Drug Administration in January 2017, which would allow certain manipulations of commercial biological products outside of the labeling instructions in order to meet a clinical need. The revised proposal improves upon an early draft by creating an option for compounders that comply with high... Read More